Walgreens Boots Alliance (WBA) Misses Q3 EPS by 8c, Cuts FY Guidance
Walgreens Boots Alliance (NASDAQ: WBA) reported Q3 EPS of $1.00, $0.08 worse than the analyst estimate of $1.08. Revenue for the quarter came in at $35.4 billion versus the consensus estimate of $34.24 billion.
GUIDANCE:
Walgreens Boots Alliance sees FY2023 EPS of $4.00-$4.05, versus the consensus of $4.46.
- Revising full-year adjusted EPS guidance to $4.00 to $4.05 from $4.45 to $4.65, to reflect consumer and category conditions, lower COVID-19 contribution, and a more cautious macroeconomic forward view
- Taking immediate actions to drive sustainable growth in adjusted operating income in fiscal 2024
- Raising Transformational Cost Management Program target from $3.5 billion to $4.1 billion in total savings
- Optimizing the U.S. Healthcare path to profitability, including an increased and accelerated synergy target for VillageMD/Summit Health of $200 million by calendar 2026
- Preliminary fiscal 2024 expectation for low- to mid-single digit adjusted operating income growth, expected to be driven by U.S. Healthcare and U.S. Retail Pharmacy; adjusted operating income growth expected to outpace adjusted EPS
For earnings history and earnings-related data on Walgreens Boots Alliance (WBA) click here.